← Eichor
Study identifier: NCT07093476 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Condition: T2DM · Diabete Type 2  ·  Sponsor: Celltrion

PhasePhase 3
Planned participants171
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Celltrion, Inc.  ·  +82 3403 9647  ·  sanghee.byun@celltrion.com

Always discuss trial participation with your own doctor first.

Locations (1)

CelltrionSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07093476